Humacyte - Earnings Call - Q2 2025

Executive Summary

• Q2 2025 revenue was $0.301M (product $0.100M; contract $0.201M); net loss narrowed to $37.7M vs $56.7M a year ago, and diluted EPS was $(0.24) vs $(0.48) YoY; press release shows $0.301M while management referenced ~$0.300M on the call.
• Commercial traction accelerated: 82 civilian hospitals now eligible to purchase Symvess through 13 VAC approvals, 12 hospitals have ordered, and July product sales of $0.3M exceeded total H1 sales; ECAT listing enables access across ~35 military treatment facilities and ~160 VA hospitals and yielded the first military sale and reorder.
• Pricing reduced to $24,250 per unit (from $29,500) effective July 1 to ease VAC adoption while maintaining margins; CMS denied NTAP for Symvess (limited impact given payer mix), and management is pursuing private payer supplemental reimbursement using the published budget impact model.
• Cost discipline: workforce and OpEx actions target ~$13.8M net savings in 2025 and up to ~$38.0M in 2026 (> $50M total vs original forecast), extending runway for commercialization and key pipeline milestones (V012 dialysis interim read in Apr 2026; supplemental BLA in H2 2026; CABG IND filing later in 2025).

What Went Well and What Went Wrong

What Went Well

• Rapid hospital adoption: 82 civilian hospitals eligible vs five in May; 12 hospitals have already ordered, with multiple reorders in July, and ECAT listing broadened DoD/VA access and drove first military sale and reorder.
• Commercial KPIs improved: July product sales of ~$0.3M exceeded total H1 sales, indicating acceleration post VAC approvals and price optimization below $25k per unit to streamline committee approvals.
• Dialysis program momentum: V007 Phase 3 data highlighted by Society for Vascular Surgery; V012 Phase 3 enrollment at 100 with interim analysis set for Apr 2026; plan for supplemental BLA in H2 2026 remains intact.

What Went Wrong

• NTAP denial by CMS on “newness” criterion, a surprise to management; however, impact seen as limited given trauma payer mix (~4.3% Medicare), pivoting to private payer discussions for supplemental reimbursement.
• Early gross margin pressure: Q2 cost of goods sold ($0.213M) exceeded product revenue ($0.100M) during ramp and capacity utilization, reflecting nascency of manufacturing scale.
• Public attacks slowed VAC timelines (now 6–9+ months vs historical 3–6 months) and added financial scrutiny, extending conversion cycles amid a tougher economic environment.

Transcript

Speaker 3

Good morning, ladies and gentlemen, and welcome to the Humacyte second quarter 2025 results conference call. Currently, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this conference is being recorded. I would now like to turn the call over to Thomas Johnson with LifeSci Advisors. Please go ahead.

Speaker 4

Thank you, Operator. Before we proceed with the call, I'd like to remind everyone that certain statements during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning in our Form 10-Q, which, after the filing, may be accessed from the investor page of the Humacyte website.

Joining me today on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer, Dale Sander, Chief Financial Officer and Chief Corporate Development Officer, and BJ Scheessele, Chief Commercial Officer. Dr. Niklason will provide a summary of the company's progress for the quarter in recent weeks, and Dale will review the company's financial results for the quarter ended June 30, 2025. Following their prepared remarks, BJ will join Laura and Dale for a Q&A session. I'll turn the call over to Dr. Laura Niklason. Go ahead, Laura.

Speaker 2

Thank you, Tom. Good morning, everyone, and thank you for joining us for our second quarter 2025 financial results and business update call. Following the landmark success of obtaining FDA approval of Cymbev for the treatment of extremity vascular trauma last year, we continue to execute on the commercial launch of this groundbreaking product. Progress during our second quarter in recent weeks was marked by continued expansion of our Value Analysis Committee, or VAC, approvals. This has led to a major expansion of the number of approvals that are now able to purchase Cymbev. Recently, we also announced that the U.S. Defense Logistics Agency granted Electronic Catalog, or E-CAT, listing approval to Cymbev. Going along with this, we have recorded our first sale to a U.S. military facility. We did encounter some headwinds during April and May due to unsubstantiated public attacks by certain detractors.

However, we've seen an acceleration in VAC approval activity and commercial sales in June and July. Coupled with the continued advancement of our acellular tissue engineered vessel, or ATEV, in our pipeline program, we believe that we're positioned for growth and value generation in 2025 and beyond. During today's call, I'll review these developments in more detail before turning the call over to Dale for a review of our financial results. BJ Scheessele, our Chief Commercial Officer, will then join us to help answer your questions. Beginning with our commercial launch of Cymbev, we're pleased by the traction that we've continued to gain in our interactions with civilian hospitals. To date, a total of 13 organizations have completed the VAC process and have approved the purchase of Cymbev. Because some of these VAC approvals include multi-hospital networks, a total of 82 civilian hospitals are now eligible to purchase Cymbev.

This is an enormous increase from the five civilian hospitals that were eligible to purchase Cymbev at our last quarterly earnings call. Furthermore, an additional 40 VAC sites are currently conducting reviews of Cymbev, and we expect that the number of hospitals eligible to purchase Cymbev will continue to grow. After VAC approval, contracting and negotiations with each individual hospital are completed before sales and shipment to that hospital can commence. Currently, our sales team is actively targeting high-volume centers, having VAC approval for contracting negotiations. July product sales of approximately $0.3 million exceeded the total sales that we recorded for the first half of the year. Also in July, we announced that Cymbev was awarded the Electronic Catalog, or E-CAT, listing approval from the U.S. Defense Logistics Agency.

E-CAT is an internet system that provides the Department of Defense and other federal agencies with access to manufacturers' and distributors' products. The E-CAT approval makes Cymbev available to healthcare professionals treating military service members, veterans, and other patients receiving care at approximately 35 military treatment facilities and approximately 160 U.S. Department of Veterans Affairs hospitals. With E-CAT approval in place, it's not generally necessary to also obtain Value Analysis Committee (VAC) approval at the military treatment facilities or VA sites. Instead, purchase is facilitated directly through the E-CAT system. Since obtaining E-CAT approval just a few weeks ago, we've already recorded our first commercial sale to a U.S. military facility. This facility is a state-of-the-art medical complex located on a major U.S. military base and provides healthcare to approximately 200,000 active duty service personnel, retirees, and their family members.

Subsequent to the initial shipment, this facility has also reordered Cymbev. We have great interest in improving the medical options that are available to healthcare professionals who are treating military personnel and their families, and we're actively advancing our discussions with additional military treatment facilities. In August, we were notified that the Centers for Medicare & Medicaid Services, or CMS, declined to approve our application for the New Technology Add-on Payment, or NTAP, for Cymbev. Our application was submitted in October of 2024, and along with the majority of applications that were submitted to CMS this cycle, our application was also denied. The reason provided by CMS was that Cymbev does not have a unique mechanism of action as compared to veins or synthetic grafts and therefore did not qualify for their newness criterion. This conclusion was extremely surprising to us.

We believe that the potential impact of the NTAP on our commercial success is fairly limited because only about 4.3% of vascular trauma patients who are falling within our approved indication are covered under Medicare reimbursement. Because private pay insurers are the most common source of reimbursement for vascular trauma patients that are falling within our indication, we're engaging in discussions with private payers about supplemental reimbursement for Cymbev in the trauma indication. We believe that the results of our budget impact model, or BIM, which we published several months ago, along with our published clinical trial results, will encourage supplemental reimbursement from private payers. I'll now turn to the ATEV program, which is our next priority, which is the dialysis access for patients with end-stage kidney failure.

We're pleased to see that results from our VO7 Phase III trial were presented in a plenary session at the Society of Vascular Surgery annual meeting in June. The VO7 results presentation that was focused on patients at high risk of fistula non-maturation was one of only three selected for special mention by the Society in their own announcement. The VO7 clinical trial enrolled a total of 242 patients, of which 110 were considered to be at high risk of fistula non-maturation. Among this high-risk cohort, functional patency at six months and secondary patency at 12 months were significantly higher in ATEV recipients as compared with fistula. Duration of access usability over the first year was also significantly higher in the ATEV group at eight months versus only 4.5 months for arteriovenous fistula with a p-value of 0.0002.

Results of the VO7 trial have also been accepted for presentation at the annual Kidney Week meeting for 2025 later this year. Women and men having diabetes and obesity make up more than half of the dialysis access market. Patients with a high risk of fistula non-maturation have historically been underserved by the current standard of care, since waiting for fistula maturation can result in prolonged catheter exposure, increased risk of infection, and additional procedures performed to assist in the maturation of the non-functioning fistula. Because of these risks, patients with fistula non-maturation have a high unmet medical need. We believe that the efficacy and safety results of the VO7 subgroup, combined with the approximately 50% fistula failure rate in this high-risk group, means that this is an excellent population for us to target in the market.

We look forward to publication of the results from the VO7 Phase III trial in a major peer-reviewed medical journal later this year. After discussions with the FDA about a supplemental BLA filing in dialysis access, we're planning to target the general subgroup of patients at high risk of fistula non-maturation. Before we file a supplemental BLA, which we anticipate later in 2026, our plan is to complete the interim analysis of the currently ongoing VO12 Phase III trial that's being conducted only in women and which compares the ATEV to fistula for hemodialysis access. To date, a total of 100 patients have been enrolled in the VO12 Phase III trial out of a target of approximately 150 patients. An interim analysis is planned when the first 80 patients reach one year of follow-up, and this enrollment threshold was achieved in April of 2025.

Subject to these interim results, Humacyte's plan is to submit a supplemental BLA in the second half of 2026, including data from VO12 and the VO7 Phase III pivotal studies to expand the Cymbev label and add AV access for hemodialysis as an indication. We're pleased with the progress that we're making in 2025, and we look forward to sharing our progress with all of you as the rest of the year unfolds with that. I'll now turn it over to Dale for a review of our financial results and other business developments.

Speaker 4

Thank you, Laura. We reported $0.3 million in revenue for the second quarter of 2025, of which $0.1 million related to U.S. sales of Cymbev. The remaining $0.2 million resulted from a research collaboration with a large medical technology company to evaluate the potential use of our bioengineered human tissue in specific cardiovascular and vascular applications. Revenue for the six months ended June 30, 2025 was $0.8 million, of which $0.2 million related to U.S. sales of Cymbev and $0.6 million resulted from the research collaboration. There was no revenue for either the second quarter or the six months ended June 30, 2024. Cost of goods sold was $0.2 million for the second quarter of 2025 and $0.4 million for the six months ended June 30, 2025, and included overhead related to unused production capacity, which was recorded as an expense in the period.

There was no cost of goods sold for either the second quarter of 2024 or the six months ended June 30, 2024. As previously discussed, during the second quarter of 2025, we implemented a plan to reduce our workforce by 30 employees, defer additional planned new hires, and reduce other operating expenses. These cost reductions were made to extend our cash runway and to better align our organizational structure with our top business objectives. These reductions were made thoughtfully, and we retained key personnel, resources, and initiatives to meet our key corporate goals and milestones.

These key objectives include the commercial launch of Cymbev, including sales, marketing, and manufacturing, completion of the VO12 Phase III pivotal study of the ATEV in dialysis, and the planned filing of a supplemental BLA with the FDA in the dialysis indication, and also the filing of an IND to commence human study of the small diameter ATEV in coronary artery bypass grafting. We estimate that we have incurred and will incur aggregate charges representing one-time cash expenditures for severance and other employee termination benefits of approximately $0.7 million, the majority of which was incurred during the second quarter of 2025. We estimate net savings due to workforce reductions, operating cost reductions, and reduced capital expenditures net of this termination severance and benefits, totaling approximately $3.8 million in 2025.

Net savings are estimated to be up to approximately $38 million in 2026, for a total estimated savings of over $50 million in 2025 and 2026 relative to the original budget forecast. Due to the timing of the cost reduction plan, any anticipated savings are expected to occur after June 30, 2025. Research and development expenses were $22.0 million for the second quarter of 2025, compared to $23.8 million for the second quarter of 2024, and were $37.4 million for the six months ended June 30, 2025, compared to $45.0 million for the six months ended June 30, 2024. The decrease in R&D expenses for the second quarter of 2025 compared to 2024 is primarily related to capitalization of overhead costs associated with the commercial manufacturing of Cymbev, offset by higher non-commercial production runs.

The decrease in R&D expenses for the six months ended June 30, 2025, compared to 2024, resulted primarily from decreased material costs as the company began capitalizing expenditures for inventory following the commercial launch of Cymbev, as well as the capitalization of overhead costs associated with this commercial manufacturing. General and administrative expenses were $7.8 million for the second quarter of 2025, compared to $5.7 million for the second quarter of 2024, and were $15.9 million for the six months ended June 30, 2025, compared to $11.1 million for the six months ended June 30, 2024. The increase in 2025 expenses compared to the prior year resulted primarily from the U.S. commercial launch of Cymbev in the vascular trauma indication, including increased personnel expenses.

Other net income or expense for the second quarter of 2025 was a net expense of $7.9 million compared to a net expense of $27.2 million for the second quarter of 2024, and other net income of $54.4 million for the six months ended June 30, 2025, compared to other net expense of $32.5 million for the six months ended June 30, 2024. The decrease in other net expense for the second quarter of 2025 and the increase in other net income for the six months ended June 30, 2025, compared to prior year results, resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with our August 2021 merger with Alpha Healthcare Acquisition Corp.

Net loss was $37.7 million for the second quarter of 2025, compared to a net loss of $56.7 million for the second quarter of 2024, and net income was $1.5 million for the six months ended June 30, 2025, compared to a net loss of $88.6 million for the six months ended June 30, 2024. The decrease in net loss for the second quarter of 2025 and the increase in net income for the six months ended June 30, 2025, compared to the prior year periods, was primarily due to the non-cash remeasurement of the contingent earnout liability described above. We had cash, cash equivalents, and restricted cash of $88.4 million as of June 30, 2025. Total cash use was $6.9 million for the six months of 2025, compared to net cash provided of $13.1 million for the first six months of 2024.

The net cash used for the first six months of 2025 included $46.7 million in net proceeds from a public offering completed in March 2025. The total cash provided for the first six months of 2024 included $43.0 million in net proceeds from a public offering completed in March 2024 and the receipt of $20 million in proceeds from a draw under a loan arrangement that did not reoccur in 2025. With that, I will turn it over to Laura for some closing remarks.

Speaker 2

Thank you, Dale. The approval and launch of Cymbev is a powerful example of our commitment to delivering truly transformative regenerative medicine solutions to improve patient outcomes. With our strong commercial execution, our promising pipelines, and our dedicated team, we're confident in our ability to continue making a positive impact. Thank you for joining our call today. Operator, we're now ready to take questions.

Speaker 3

Thank you. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from the line of Ryan Benjamin Zimmerman with BTIG. Please proceed with your question.

Speaker 4

Good morning. Thanks for taking our questions, Laura and Dale. Appreciate it. Maybe just to start on some of the dynamics commercially, Laura. If you think about second quarter volume versus what's taken place in July, and you noted that uptick, has anything changed in your view that you think you can identify in July that now becomes kind of more part of your commercial strategy in terms of launching Cymbev?

Speaker 2

Thank you for that, Ryan. A lot of it is just passage of time. We really embarked on the Value Analysis Committee process in late February, early March, and many of these committees just take months and months. Part of it was that. Part of the uptick in hospitals eligible to purchase Cymbev was the fact that we did have several hospital systems approve the product in their Value Analysis Committee process. I would also say we're looking at, we've looked at decreasing the price of Cymbev from $29,500 to $24,250. This decrease in price still allows us to have good margins on the product, but by coming in below $25,000, this has increased the ease with which Value Analysis Committee committees can review our product and agree to bring it onto the shelf.

Speaker 4

Yeah, that was my next question around pricing strategy, just looking at the unit volumes versus the revenue. Is that now something that you're making standard across all facilities? I guess, how do we think about your pricing strategy over time? If this is the new price point that we should think about going forward?

Speaker 2

I think this is the new price point that we should think about. This was a price point that we put into place on July 1. That certainly corresponds, that had some overlap with the uptick in sale. I don't think that was the entire thing, though, because we clearly had centers that were buying before the decrease in price. The decrease in price will now be standard for the next year. Just as with any other medical products, we will consider annual price increases on a yearly basis.

Speaker 4

Okay. All right. Thanks for taking my questions. I'll hop back in queue.

Speaker 3

Thank you. Our next question comes from the line of Joshua Thomas Jennings with TD Cowen. Please proceed with your question.

Speaker 1

Hi. Good morning, Laura and Dale. Thanks for the questions. I wanted to just ask, I know you talked about some of the headwinds early in the year from substantiated attacks by detractors, and I just wanted to review the accrual of real-world evidence and any registry data that would build over the coming quarters, years that would significantly bury any detractor noise.

Speaker 2

As we've mentioned to the market, we do have some post-approval commitments with the FDA to essentially create a registry of trauma patients and follow at least 100 patients for a year. We're still working on that protocol with the FDA, so that registry hasn't officially kicked off yet, but we're on time, we're meeting our timelines and our milestones for that. I actually think that the real-world evidence is going to continue to accrue in different hospitals that are using the product. Multiple hospitals have reordered the product, and there are people who are using it with a tremendous amount of success. I think that word of mouth, but also publications from real-world use of the product, will definitely help to solidify our commercial position.

Speaker 1

Josh, it's BJ here. I can.

Speaker 4

Yep, thanks.

Speaker 1

Real quick. Oh, Josh, it's BJ here. I was just going to jump in and add to what Laura was saying. Obviously, we had published our budget impact model, but we continue to publish our trauma data, both civilian and military, be it the U.S. and, you know, work in Ukraine. First it was 30-year data, have upcoming one-year data to continue to show the durability of our product. I think that's important. Just to round out around the public attacks, how that has played out, and it was somewhat to Ryan's point too, is that it's just really slowed the approval process. The majority of the fact is it's just now taking longer to get through hospitals, but have been able to overcome that. I think that's also, the tough economy has made it tougher for any new products.

You talk to other companies that have launched new products recently, and it's just, in general, a longer process. Given our full funnel and working through this process and the success that we had end of June and beginning of July, I feel that we're turning the corner. Thanks for that. I wanted to touch on the inclusion on the electronic catalog and opening up access to the 190 military treatment facilities. Can you help just thinking through a commercial effort in this VA hospital channel to drive increased traction? I know you've had your first order, but wanted to kind of get help thinking about back half of the year in this channel and into 2026 and how you guys can go on offense more fully here.

Speaker 4

Yeah, kind of how I look at it is both the individual hospital work and then obviously a collection of hospitals or some type of larger purchase. In the near term with the E-CAT, again, opens up the military treatment facilities. I'd say a good number of them are targets of ours and then a much larger number of VAs, but it'll be more selective targets within the VAs where they obviously perform trauma procedures. A minority of them, we've had the initial order, reorder. We've been able to meet with some of the other major facilities, some that were involved in our clinical work, others that we've had peer-to-peer discussions, those that have used it in the military introducing us to other hospitals and surgeons. I think through the rest of this year, we'll be penetrating those hospitals, those hospitals of targets of ours.

In parallel, there is obviously the procurement process for some type of bulk purchase, stockpiling that we are working in parallel. I believe as we have more successful military experience, that in concert with work in the procurement process, as we end the year and roll into next year, that the larger purchase becomes more viable for us.

Speaker 1

Thank you for that as well. Lastly, on the AV access indication, you've secured the 80 patients enrolled for that back in April and have 100 today. Is it okay to forecast enrollment completion for the trial for the 150 patients by year-end 2025 and maybe review the timelines for interim analysis once you get the last patient follow-up, 12-month follow-up in April 2026 and how that could play out next year? Thanks for taking all the questions.

Speaker 2

Yeah, Josh. We're going to aim to complete 150 patients by the end of the year. It's always hard to know. It's very hard to predict trial enrollment. It could be before the end of the year, it could be a little after the end of the year. Hard to know. Regardless, the interim analysis is now fixed, as you mentioned, in April of 2026. I would imagine we will have top-line results from that, certainly by May or June for that interim analysis. We would be able to share those results with the market. As far as the way the trial is designed, the way it was originally written is that if we are successful on the interim analysis and if our vessel is superior to fistula with those 80 patients, then we're done. The trial is successful and we move on.

In that situation, we would then, as we've said, anticipate filing a supplemental BLA in the second half of 2026. If we don't hit that interim analysis, we just continue following the 150 patients, and we would feel pretty confident that we're going to hit the analysis at 150. Since all of those patients would already have been enrolled, the additional time lag there would be, I don't know, six or eight months, something like that.

Speaker 1

Thanks for reviewing that, Laura. Appreciate it.

Speaker 3

Thank you. Our next question comes from the line of Swayampakula Ramakanth with H.C. Wainwright. Please proceed with your question.

Speaker 5

Thank you. Good morning, Laura and Dale. A couple of quick questions from me. The first question is, looking back at the first quarter press release, you were stating 45 hospitals had initiated the VAC process. How many of those have actually ordered at this point? Also, any insight into what the timeline is in general for getting through the VAC to the ordering process itself?

Speaker 4

Laura, I can jump in on this.

Speaker 2

Yeah, why don't you take that, BJ? You'll be better. Yeah.

Speaker 4

Feel free to add. It is a mix of hospitals that we started early and then hospitals that we've approached more recently, a mix of them that have worked through the process to then have the approval to then be able to sell into. As we stated in the press release, we've had 12 hospitals to date order Cymbev and then a number of them actually already having reordered. Our success rate with VAC is strong. As I mentioned before, in Q2, some of the public attacks did slow us down with value analysis committees. That is where I was mentioning that from my commercial experience, you could think of three to six months to get through a value analysis committee and then obviously contracting on the back end.

We view that as six to nine plus months now, in general because of the economy, but also some of the attacks on us. As I also mentioned, we have a full sales funnel and not all of them take the upper end and not all of them the lower end. If you have a full funnel, you always have something coming through on the back end with approval and then be able to sell into. That is something that we've accounted for and, as I mentioned, believe that we're turning the corner on.

Speaker 5

Thank you for that. The second question is regarding the negative decision by the CMS. What sort of an impact, if any, would it have on the private payers' reimbursement decisions?

Speaker 4

Yeah, Laura, I can jump in on that one too, and feel free.

Speaker 2

Sure, sure.

Speaker 4

As Laura had mentioned, obviously, a disappointment for us. Newness. I think we can kind of all agree that our product is new and a one-of-one type. We asked, we were denied. That was disappointing. There are pathways that we think you can refile. That's something that we will look at and consider. When it rolls to, again, private payers are the ones that pay the majority of these vascular trauma repair type of procedures in these patients. We believe that our product is new, but more importantly, how private payers view, in essence, being able to pay for a product and writing procedures behind that is really based on your clinical and health economic data.

Not only of what we've gathered, but published, peer-reviewed, both on the clinical side and following these patients over time, and our budget impact model that's also published of reducing costly complications like infections and amputations versus products that are used today, that private insurers will see this as a strong value proposition and work with them to get them to incrementally pay for our product.

Speaker 5

Thanks. Thanks for taking my questions.

Speaker 2

I guess I would add to that, RK, that our success rate with Value Analysis Committees has been pretty good, and we've gotten into an enormous number of hospitals just in the last couple of months, up to 84, which is very exciting for us. When hospitals look at the financial prospects for a product, they're really just looking at the puts and takes on that initial hospitalization because this is a DRG process. Hospitals are focused on the cost to take care of that patient just during the hospitalization. Payers, on the other hand, are on the hook for longer-term complications, particularly with infection and amputation, which drive a lot of costs in the initial hospitalization but continue to drive costs after discharge because of readmissions, because of physical therapy, because of repeated procedures. Insurance companies are on the hook for all of that.

I believe that our financial case for providing a supplemental payment for Cymbev and trauma is going to be even stronger with private payers. We've got our ducks in a row. We're lining up private payers, and we're going to go out and start having those conversations very soon.

Speaker 5

Thanks. Thank you both.

Speaker 3

Thank you. Our next question comes from the line of Bruce David Jackson with The Benchmark Company. Please proceed with your question.

Speaker 0

Hi. Good morning, and thank you for taking my question. I was wondering if we could get an update on the coronary artery bypass graft program.

Speaker 2

Yes, absolutely. We have a paper that's been accepted for publication about our primate results in coronary artery bypass that we expect to publish in the near future. We will put out a press release with that when that happens. We're also making excellent headway on our IND filing with the FDA. We are in the process of pulling that filing together, and we expect to have that in later in 2025 as we've messaged the market previously. After we submit the IND, we anticipate that the FDA will spend some time looking at it. We're a first-in-class product, and we're going into the human coronary system. We expect that there will be some review time. Once they approve that, and I certainly anticipate that they will, we would start our clinical trial sometime in 2026. Everything is on track with what we've messaged the market previously.

Speaker 4

Okay, great. Thank you. That's it for me.

Speaker 3

Thank you. Ladies and gentlemen, that concludes our question and answer session. I'll turn the floor back to Dr. Niklason for any final comments.

Speaker 2

Thank you, everyone, for joining us this morning. Our fantastic commercial team has continued to execute during this exciting time. I personally am very excited by the fact that so many hospitals and both civilian and military treatment facilities and VAs are now eligible to purchase our product. More than 200 facilities. If we compare that to the five facilities that were on tap to purchase our product just three months ago, I think this is huge progress. We're going to continue working on the contract negotiations and continue shipping and selling product. It's make product, sell product. That's where our focus is. I'm so glad that we're getting traction here. I appreciate your time, and I look forward to sharing more results with you later this year.

Speaker 3

Thank you. This concludes today's conference call. You may disconnect your lines at this time. Thank you for your participation.